Cetyl myristoleate (CMO) is the common name for cis-9-cetyl myristoleate. CMO was discovered in 1972 by Harry W. Diehl, Ph.D., a researcher at the National Institutes of Health. At the time, Dr. Diehl was responsible for testing anti-inflammatory drugs on lab animals. In order for him to test the drugs, he first had to artificially induce arthritis in the animals by injecting a heat-killed bacterium called Freund’s adjuvant. Dr. Diehl discovered that Swiss albino mice did not get arthritis after injection of Freund’s adjuvant. Eventually, he was able to determine that cetyl myristoleate was the factor present naturally in mice that was responsible for this protection. When CMO was injected into various strains of rats, it offered the same protection against arthritis.1
Where is it found?
Cetyl myristoleate is found in certain animals, including cows, whales, beavers, and mice. As a nutritional supplement it is found in a highly purified, refined form in capsules and tablets. CMO is also available in creams and lotions for topical application.
CMO has been used in connection with the following conditions (refer to the individual health concern for complete information):
| Science Rating | Health Concerns |
|---|---|
 | Osteoarthritis Rheumatoid arthritis |
 Reliable and relatively consistent scientific data showing a substantial health benefit. Contradictory, insufficient, or preliminary studies suggesting a health benefit or minimal health benefit. For an herb, supported by traditional use but minimal or no scientific evidence. For a supplement, little scientific support and/or minimal health benefit. | |
Who is likely to be deficient?
As cetyl myristoleate is not an essential nutrient, no deficiency state exists.
How much is usually taken?
Generally, CMO is taken in the amount of 400 to 500 mg daily for 30 days.
Are there any side effects or interactions?
No side effects or drug interactions have been reported.
References
1. Diehl HW, May EL. Cetyl myristoleate isolated from Swiss albino mice: an apparent protective agent against adjuvant arthritis in rats. J Pharm Sci 1994;83:296-9.
Copyright 2007, Healthnotes, Inc., 1505 S.E. Gideon St., Suite 200, Portland, Oregon 97202, www.Healthnotes.com.
2006-09-07
